Table of Contents Author Guidelines Submit a Manuscript
Cardiology Research and Practice
Volume 2010, Article ID 649164, 12 pages
http://dx.doi.org/10.4061/2010/649164
Review Article

Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention

1Cardiology Section, Department of Medicine, The Aga Khan University, Stadium Road, P.O. Box 3500, Karachi 74800, Pakistan
2MBBS Program, The Aga Khan University, B-4, Al-Qahir Apt., Violet Street, Garden East, Karachi 74550, Pakistan

Received 29 March 2010; Revised 21 July 2010; Accepted 25 August 2010

Academic Editor: Christian Wilhelm Hamm

Copyright © 2010 Sana Shoukat et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. H. Ix, M. G. Shlipak, H. H. Liu, N. B. Schiller, and M. A. Whooley, “Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: the heart and soul study,” Journal of the American Society of Nephrology, vol. 14, no. 12, pp. 3233–3238, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. N. S. Anavekar, J. J. V. McMurray, E. J. Velazquez et al., “Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction,” New England Journal of Medicine, vol. 351, no. 13, pp. 1285–1295, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. M. G. Shlipak, G. L. Smith, S. S. Rathore, B. M. Massie, and H. M. Krumholz, “Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial,” Journal of the American Society of Nephrology, vol. 15, no. 8, pp. 2195–2203, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. N. Dimković, “Cardiovascular diseases in patients with chronic renal diseases,” Srpski Arhiv za Celokupno Lekarstvo, vol. 136, pp. 135–141, 2008. View at Google Scholar · View at Scopus
  5. T. Ohtake, S. Kobayashi, H. Moriya et al., “High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination,” Journal of the American Society of Nephrology, vol. 16, no. 4, pp. 1141–1148, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. A. Levin, “Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis,” Seminars in Dialysis, vol. 16, no. 2, pp. 101–105, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. A. J. Collins, “Cardiovascular mortality in end-stage renal disease,” American Journal of the Medical Sciences, vol. 325, no. 4, pp. 163–167, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C.-Y. Hsu, “Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization,” New England Journal of Medicine, vol. 351, no. 13, pp. 1296–1370, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. R. Mehran and E. Nikolsky, “Contrast-induced nephropathy: definition, epidemiology, and patients at risk,” Kidney International, no. 100, supplement, pp. S11–S15, 2006. View at Google Scholar · View at Scopus
  10. J. R. Brown, D. J. Malenka, J. T. DeVries et al., “Transient and persistent renal dysfunction are predictors of survival after percutaneous coronary intervention: insights from the Dartmouth Dynamic Registry,” Catheterization and Cardiovascular Interventions, vol. 72, no. 3, pp. 347–354, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. H. M. Sadeghi, G. W. Stone, C. L. Grines et al., “Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction,” Circulation, vol. 108, no. 22, pp. 2769–2775, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. H. S. Thomsen and S. K. Morcos, “Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines,” British Journal of Radiology, vol. 76, no. 908, pp. 513–518, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. H. S. Thomsen and S. K. Morcos, “Contrast-medium-induced nephropathy: is there a new consensus? A review of published guidelines,” European Radiology, vol. 16, no. 8, pp. 1835–1840, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. R. G. Brindis, S. Fitzgerald, H. V. Anderson, R. E. Shaw, W. S. Weintraub, and J. F. Williams, “The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR): building a national clinical data repository,” Journal of the American College of Cardiology, vol. 37, no. 8, pp. 2240–2244, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. K. J. Harjai, A. Raizada, C. Shenoy et al., “A Comparison of contemporary definitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system,” American Journal of Cardiology, vol. 101, no. 6, pp. 812–819, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. P. Parfrey, “The clinical epidemiology of contrast-induced nephropathy,” CardioVascular and Interventional Radiology, vol. 28, supplement 2, pp. S3–S11, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. C. S. Rihal, S. C. Textor, D. E. Grill et al., “Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention,” Circulation, vol. 105, no. 19, pp. 2259–2264, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Haller and I. Hizoh, “The cytotoxicity of iodinated radiocontrast agents on renal cells in vitro,” Investigative Radiology, vol. 39, no. 3, pp. 149–154, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. P. A. McCullough, “Radiocontrast-induced acute kidney injury,” Nephron Physiology, vol. 109, no. 4, pp. p61–p72, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. R. E. Katholi, W. T. Woods Jr., G. J. Taylor et al., “Oxygen free radicals and contrast nephropathy,” American Journal of Kidney Diseases, vol. 32, no. 1, pp. 64–71, 1998. View at Google Scholar · View at Scopus
  21. S. N. Heyman, J. Reichman, and M. Brezis, “Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia,” Investigative Radiology, vol. 34, no. 11, pp. 685–691, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Dickenmann, T. Oettl, and M. J. Mihatsch, “Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes,” American Journal of Kidney Diseases, vol. 51, no. 3, pp. 491–503, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. J. F. Moreau, D. Droz, and L. H. Noel, “Tubular nephrotoxicity of water-soluble iodinated contrast media,” Investigative Radiology, vol. 15, no. 6, pp. S54–S60, 1980. View at Google Scholar · View at Scopus
  24. S. L. Chen, J. Zhang, F. Yei et al., “Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine,” International Journal of Cardiology, vol. 126, no. 3, pp. 407–413, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. M. J. Gussenhoven, J. Ravensbergen, J. H. van Bockel et al., “Renal dysfunction after angiography; a risk factor analysis in patients with peripheral vascular disease,” Journal of Cardiovascular Surgery, vol. 32, p. 81, 1991. View at Google Scholar
  26. G. Dangas, I. Iakovou, E. Nikolsky et al., “Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables,” American Journal of Cardiology, vol. 95, no. 1, pp. 13–19, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. C. J. Davidson, M. Hlatky, K. G. Morris et al., “Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. A prospective trial,” Annals of Internal Medicine, vol. 110, no. 2, pp. 119–124, 1989. View at Google Scholar · View at Scopus
  28. P. A. McCullough, A. Adam, C. R. Becker et al., “Risk prediction of contrast-induced nephropathy,” American Journal of Cardiology, vol. 98, no. 6, pp. 27–36, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. P. A. McCullough, R. Wolyn, L. L. Rocher, R. N. Levin, and W. W. O'Neill, “Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality,” American Journal of Medicine, vol. 103, no. 5, pp. 368–375, 1997. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Nikolsky, E. D. Aymong, G. Dangas, and R. Mehran, “Radiocontrast nephropathy: identifying the high-risk patient and the implications of exacerbating renal function,” Reviews in Cardiovascular Medicine, vol. 4, supplement 1, pp. S7–S14, 2003. View at Google Scholar · View at Scopus
  31. S. M. Bagshaw and B. F. Culleton, “Contrast-induced nephropathy: epidemiology and prevention,” Minerva Cardioangiologica, vol. 54, no. 1, pp. 109–129, 2006. View at Google Scholar · View at Scopus
  32. O. Toprak, M. Cirit, M. Yesil et al., “Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease,” Nephrology Dialysis Transplantation, vol. 22, no. 3, pp. 819–826, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. A. S. Berns, “Nephrotoxicity of contrast media,” Kidney International, vol. 36, no. 4, pp. 730–740, 1989. View at Google Scholar · View at Scopus
  34. G. Marenzi, G. Lauri, E. Assanelli et al., “Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction,” Journal of the American College of Cardiology, vol. 44, no. 9, pp. 1780–1785, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. R. Mehran, E. D. Aymong, E. Nikolsky et al., “A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation,” Journal of the American College of Cardiology, vol. 44, no. 7, pp. 1393–1399, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. J. K. Kahn, B. D. Rutherford, D. R. McConahay et al., “High-dose contrast agent administration during complex coronary angioplasty,” American Heart Journal, vol. 120, no. 3, pp. 533–536, 1990. View at Publisher · View at Google Scholar · View at Scopus
  37. M. A. Rosovsky, H. Rusinek, A. Berenstein, S. Basak, A. Setton, and P. K. Nelson, “High-dose administration of nonionic contrast media: a retrospective review,” Radiology, vol. 200, no. 1, pp. 119–122, 1996. View at Google Scholar · View at Scopus
  38. G. C. Kane, B. J. Doyle, A. Lerman, G. W. Barsness, P. J. Best, and C. S. Rihal, “Ultra-low contrast volumes reduce rates of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography,” Journal of the American College of Cardiology, vol. 51, no. 1, pp. 89–90, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. S. F. Mekan, M. A. Rabbani, M. Azhar-Uddin, and S. S. Ali, “Radiocontrast nephropathy: is it dose related or not?” Journal of the Pakistan Medical Association, vol. 54, no. 7, pp. 372–374, 2004. View at Google Scholar · View at Scopus
  40. W. K. Laskey, C. Jenkins, F. Selzer et al., “Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention,” Journal of the American College of Cardiology, vol. 50, no. 7, pp. 584–590, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. B. J. Barrett and E. J. Carlisle, “Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media,” Radiology, vol. 188, no. 1, pp. 171–178, 1993. View at Google Scholar · View at Scopus
  42. M. R. Rudnick, S. Goldfarb, L. Wexler et al., “Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study,” Kidney International, vol. 47, pp. 254–261, 1995. View at Google Scholar
  43. P. Aspelin, P. Aubry, S.-G. Fransson, R. Strasser, R. Willenbrock, and K. J. Berg, “Nephrotoxic effects in high-risk patients undergoing angiography,” New England Journal of Medicine, vol. 348, no. 6, pp. 491–499, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. P. A. McCullough, M. E. Bertrand, J. A. Brinker, and F. Stacul, “A meta-analysis of the renal safety of isosmolar Iodixanol compared with low-osmolar contrast media,” Journal of the American College of Cardiology, vol. 48, no. 4, pp. 692–699, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. S.-H. Jo, T.-J. Youn, B.-K. Koo et al., “Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography. The recover study: a randomized controlled trial,” Journal of the American College of Cardiology, vol. 48, no. 5, pp. 924–930, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. R. Mehran, “ICON—a prospective, randomized, placebo-controlled trial of ioxaglate vs iodixanol in patients at increased risk for contrast nephropathy,” TCT, 2006.
  47. R. J. Solomon, M. K. Natarajan, S. Doucet et al., “Cardiac angiography in renally impaired patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease,” Circulation, vol. 115, no. 25, pp. 3189–3196, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. T. Nicholson and M. Downes, “Contrast nephrotoxicity and iso-osmolar contrast agents: implications of NEPHRIC,” Clinical Radiology, vol. 58, no. 9, pp. 659–660, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. H. S. Thomsen, S. K. Morcos, C. M. Erley et al., “The ACTIVE trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography,” Investigative Radiology, vol. 43, no. 3, pp. 170–178, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. P. B. Persson, P. Hansell, and P. Liss, “Pathophysiology of contrast medium-induced nephropathy,” Kidney International, vol. 68, no. 1, pp. 14–22, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. B. A. Bartholomew, K. J. Harjai, S. Dukkipati et al., “Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification,” American Journal of Cardiology, vol. 93, no. 12, pp. 1515–1519, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. S. H. Hou, D. A. Bushinsky, and J. B. Wish, “Hospital-acquired renal insufficiency: a prospective study,” American Journal of Medicine, vol. 74, no. 2, pp. 243–248, 1983. View at Google Scholar · View at Scopus
  53. E. M. Levy, C. M. Viscoli, and R. I. Horwitz, “The effect of acute renal failure on mortality: a cohort analysis,” Journal of the American Medical Association, vol. 275, no. 19, pp. 1489–1494, 1996. View at Publisher · View at Google Scholar · View at Scopus
  54. P. J. M. Best, R. Lennon, H. H. Ting et al., “The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions,” Journal of the American College of Cardiology, vol. 39, no. 7, pp. 1113–1119, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. C. M. Erley, “Does hydration prevent radiocontrast-induced acute renal failure?” Nephrology Dialysis Transplantation, vol. 14, no. 5, pp. 1064–1066, 1999. View at Publisher · View at Google Scholar · View at Scopus
  56. R. Solomon, C. Werner, D. Mann, J. D'Elia, and P. Silva, “Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents,” New England Journal of Medicine, vol. 331, no. 21, pp. 1416–1420, 1994. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. M. A. Stevens, P. A. McCullough, K. J. Tobin et al., “A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of radiocontrast induced nephropathy clinical evaluation,” Journal of the American College of Cardiology, vol. 33, p. 403, 1999. View at Google Scholar
  58. A. J. Taylor, D. Hotchkiss, R. W. Morse, and J. McCabe, “PREPARED: preparation for angiography in renal dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction,” Chest, vol. 114, no. 6, pp. 1570–1574, 1998. View at Google Scholar · View at Scopus
  59. H. S. Trivedi, H. Moore, S. Nasr et al., “A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity,” Nephron Clinical Practice, vol. 93, no. 1, pp. C29–C34, 2003. View at Google Scholar · View at Scopus
  60. C. Mueller, G. Buerkle, H. J. Buettner et al., “Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty,” Archives of Internal Medicine, vol. 162, no. 3, pp. 329–336, 2002. View at Google Scholar · View at Scopus
  61. F. Stacul, A. Adam, C. R. Becker et al., “Strategies to reduce the risk of contrast-induced nephropathy,” American Journal of Cardiology, vol. 98, no. 6, pp. 59–77, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. C. Briguori, F. Airoldi, D. D'Andrea et al., “Renal insufficiency following contrast media administration trial (REMEDIAL): a randomized comparison of 3 preventive strategies,” Circulation, vol. 115, no. 10, pp. 1211–1217, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. A. Recio-Mayoral, M. Chaparro, B. Prado et al., “The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study,” Journal of the American College of Cardiology, vol. 49, no. 12, pp. 1283–1288, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. G. J. Merten, W. P. Burgess, L. V. Gray et al., “Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial,” Journal of the American Medical Association, vol. 291, no. 19, pp. 2328–2334, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. A. Bouzas-Mosquera and A. Recio-Mayoral, “Sodium bicarbonate, N-acetylcysteine, and saline for the prevention of contrast-induced nephropathy,” American Heart Journal, vol. 155, no. 4, article no. e31, 2008. View at Publisher · View at Google Scholar · View at PubMed
  66. D. Castini, S. Lucreziotti, L. Bosotti et al., “Prevention of contrast-induced nephropathy: a single center randomized study,” Clinical Cardiology, vol. 33, no. 3, pp. E63–E68, 2010. View at Publisher · View at Google Scholar · View at PubMed
  67. E. E. Ozcan, S. Guneri, B. Akdeniz et al., “Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial,” American Heart Journal, vol. 154, no. 3, pp. 539–544, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. A. Vasheghani-Farahani, G. Sadigh, S. E. Kassaian et al., “Sodium bicarbonate in preventing contrast nephropathy in patients at risk for volume overload: a randomized controlled trial,” Journal of Nephrology, vol. 23, p. 216, 2010. View at Google Scholar
  69. A. Vasheghani-Farahani, G. Sadigh, S. E. Kassaian et al., “sodium bicarbonate plus isotonic saline versus saline for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a randomized controlled trial,” American Journal of Kidney Diseases, vol. 54, no. 4, pp. 610–618, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. V. Kunadian, A. Zaman, I. Spyridopoulos, and W. Qiu, “Sodium bicarbonate for the prevention of contrast induced nephropathy: a meta-analysis of published clinical trials,” European Journal of Radiology. In press.
  71. S. D. Navaneethan, S. Singh, S. Appasamy, R. E. Wing, and A. R. Sehgal, “Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis,” American Journal of Kidney Diseases, vol. 53, no. 4, pp. 617–627, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. S. Zoungas, T. Ninomiya, R. Huxley et al., “Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy,” Annals of Internal Medicine, vol. 151, no. 9, pp. 631–638, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. L. C. Clavijo, T. L. Pinto, P. K. Kuchulakanti et al., “Effect of a rapid intra-arterial infusion of dextrose 5% prior to coronary angiography on frequency of contrast-induced nephropathy in high-risk patients,” American Journal of Cardiology, vol. 97, no. 7, pp. 981–983, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. J. DiMari, J. Megyesi, N. Udvarhelyi, P. Price, R. Davis, and R. Safirstein, “N-acetyl cysteine ameliorates ischemic renal failure,” American Journal of Physiology, vol. 272, no. 3, pp. F292–F298, 1997. View at Google Scholar · View at Scopus
  75. M. Tepel, M. Van Der Giet, C. Schwarzfeld, U. Laufer, D. Liermann, and W. Zidek, “Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine,” New England Journal of Medicine, vol. 343, no. 3, pp. 180–184, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. L. J. Diaz-Sandoval, B. D. Kosowsky, and D. W. Losordo, “Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial),” American Journal of Cardiology, vol. 89, no. 3, pp. 356–358, 2002. View at Publisher · View at Google Scholar · View at Scopus
  77. A. D. Azmus, C. Gottschall, A. Manica et al., “Effectiveness of acetylcysteine in prevention of contrast nephropathy,” Journal of Invasive Cardiology, vol. 17, no. 2, pp. 80–84, 2005. View at Google Scholar · View at Scopus
  78. G. Marenzi, E. Assanelli, I. Marana et al., “N-acetylcysteine and contrast-induced nephropathy in primary angioplasty,” New England Journal of Medicine, vol. 354, no. 26, pp. 2773–2782, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. J. Kay, W. H. Chow, T. M. Chan et al., “Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial,” Journal of the American Medical Association, vol. 289, no. 5, pp. 553–558, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. J. G. Webb, G. E. Pate, K. H. Humphries et al., “A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect,” American Heart Journal, vol. 148, no. 3, pp. 422–429, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. F. Boccalandro, M. Amhad, R. W. Smalling, and S. Sdringola, “Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast,” Catheterization and Cardiovascular Interventions, vol. 58, no. 3, pp. 336–341, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. C. Briguori, F. Manganelli, P. Scarpato et al., “Acetylcysteine and contrast agent-associated nephrotoxicity,” Journal of the American College of Cardiology, vol. 40, no. 2, pp. 298–303, 2002. View at Publisher · View at Google Scholar · View at Scopus
  83. C. Briguori, A. Colombo, A. Violante et al., “Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity,” European Heart Journal, vol. 25, no. 3, pp. 206–211, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  84. C. S. R. Baker, A. Wragg, S. Kumar, R. De Palma, L. R. I. Baker, and C. J. Knight, “A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study,” Journal of the American College of Cardiology, vol. 41, no. 12, pp. 2114–2118, 2003. View at Publisher · View at Google Scholar · View at Scopus
  85. B. K. Nallamothu, K. G. Shojania, S. Saint et al., “Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis,” American Journal of Medicine, vol. 117, no. 12, pp. 938–947, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. S. M. Bagshaw and W. A. Ghali, “Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic reveiw and meta-analysis,” BMC Medicine, vol. 2, article no. 38, 2004. View at Publisher · View at Google Scholar · View at PubMed
  87. M. Maioli, A. Toso, M. Leoncini et al., “Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention,” Journal of the American College of Cardiology, vol. 52, no. 8, pp. 599–604, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. G. Patti, A. Nusca, M. Chello et al., “Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention,” American Journal of Cardiology, vol. 101, no. 3, pp. 279–285, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  89. N. Attallah, L. Yassine, J. Musial, J. Yee, and K. Fisher, “The potential role of statins in contrast nephropathy,” Clinical Nephrology, vol. 62, no. 4, pp. 273–278, 2004. View at Google Scholar · View at Scopus
  90. S. Khanal, N. Attallah, D. E. Smith et al., “Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions,” American Journal of Medicine, vol. 118, no. 8, pp. 843–849, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  91. A. Toso, M. Maioli, M. Leoncini et al., “Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease,” American Journal of Cardiology, vol. 105, no. 3, pp. 288–292, 2010. View at Google Scholar
  92. J. Xinwei, F. Xianghua, Z. Jing et al., “Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention,” American Journal of Cardiology, vol. 104, no. 4, pp. 519–524, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  93. A. Kapoor, N. Sinha, R. K. Sharma et al., “Use of dopamine in prevention of contrast induced acute renal failure—a randomised study,” International Journal of Cardiology, vol. 53, no. 3, pp. 233–236, 1996. View at Publisher · View at Google Scholar
  94. M. Gare, Y. S. Haviv, A. Ben-Yehuda et al., “The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography,” Journal of the American College of Cardiology, vol. 34, no. 6, pp. 1682–1688, 1999. View at Publisher · View at Google Scholar
  95. A. S. Abizaid, C. E. Clark, G. S. Mintz et al., “Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency,” American Journal of Cardiology, vol. 83, no. 2, pp. 260–263, 1999. View at Publisher · View at Google Scholar
  96. J. A. Tumlin, A. Wang, P. T. Murray, and V. S. Mathur, “Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy,” American Heart Journal, vol. 143, no. 5, pp. 894–903, 2002. View at Publisher · View at Google Scholar
  97. G. W. Stone, P. A. McCullough, J. A. Tumlin et al., “Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial,” Journal of the American Medical Association, vol. 290, no. 17, pp. 2284–2291, 2003. View at Publisher · View at Google Scholar · View at PubMed
  98. P. S. Teirstein, M. J. Price, V. S. Mathur et al., “Differential effects between intravenous and targeted renal delivery of fenoldopam on renal function and blood pressure in patients undergoing cardiac catheterization,” American Journal of Cardiology, vol. 97, no. 7, pp. 1076–1081, 2006. View at Google Scholar
  99. W. Huber, K. Ilgmann, M. Page et al., “Effect of theophylline on contrast material-induced nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study,” Radiology, vol. 223, no. 3, pp. 772–779, 2002. View at Google Scholar
  100. A. Kapoor, S. Kumar, S. Gulati, S. Gambhir, R. S. Sethi, and N. Sinha, “The role of theophylline in contrast-induced nephropathy: a case-control study,” Nephrology Dialysis Transplantation, vol. 17, no. 11, pp. 1936–1941, 2002. View at Google Scholar
  101. C. M. Erley, S. H. Duda, D. Rehfuss et al., “Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline,” Nephrology Dialysis Transplantation, vol. 14, no. 5, pp. 1146–1149, 1999. View at Publisher · View at Google Scholar
  102. H.-H. Neumayer, W. Junge, A. Kufner, and A. Wenning, “Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial,” Nephrology Dialysis Transplantation, vol. 4, no. 12, pp. 1030–1036, 1989. View at Google Scholar
  103. M. Carraro, W. Mancini, M. Artero et al., “Dose effect of nitrendipine on urinary enzymes and microproteins following non-ionic radiocontrast administration,” Nephrology Dialysis Transplantation, vol. 11, no. 3, pp. 444–448, 1996. View at Google Scholar
  104. Z. Khoury, J. R. Schlicht, J. Como et al., “The effect of prophylactic nifedipine on renal function in patients administered contrast media,” Pharmacotherapy, vol. 15, no. 1 I, pp. 59–65, 1995. View at Google Scholar
  105. M. H. Sketch Jr., A. Whelton, E. Schollmayer et al., “Prevention of contrast media-induced renal dysfunction with prostaglandin E1: a randomized, double-blind, placebo-controlled study,” American Journal of Therapeutics, vol. 8, no. 3, pp. 155–162, 2001. View at Google Scholar
  106. K. Spargias, E. Alexopoulos, S. Kyrzopoulos et al., “Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention,” Circulation, vol. 110, no. 18, pp. 2837–2842, 2004. View at Publisher · View at Google Scholar · View at PubMed
  107. B. R. C. Kurnik, R. L. Allgren, F. C. Center, R. J. Solomon, E. R. Bates, and L. S. Weisberg, “Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy,” American Journal of Kidney Diseases, vol. 31, no. 4, pp. 674–680, 1998. View at Google Scholar
  108. B. Vogt, P. Ferrari, C. Schönholzer et al., “Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful,” American Journal of Medicine, vol. 111, no. 9, pp. 692–698, 2001. View at Publisher · View at Google Scholar
  109. T. Lehnert, E. Keller, K. Gondolf et al., “Effect of haemodialysis after contrast medium administration in patients with renal insufficiency,” Nephrology Dialysis Transplantation, vol. 13, no. 1, pp. 358–362, 1998. View at Google Scholar
  110. G. Marenzi, G. Lauri, J. Campodonico et al., “Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients,” American Journal of Medicine, vol. 119, no. 2, pp. 155–162, 2006. View at Publisher · View at Google Scholar · View at PubMed
  111. G. Marenzi, I. Marana, G. Lauri et al., “The prevention of radiocontrast-agent-induced nephropathy by hemofiltration,” New England Journal of Medicine, vol. 349, no. 14, pp. 1333–1340, 2003. View at Publisher · View at Google Scholar · View at PubMed
  112. D. J. Spinosa, J. F. Angle, K. D. Hagspiel, J. A. Kern, G. D. Hartwell, and A. H. Matsumoto, “Lower extremity arteriography with use of iodinated contrast material or gadodiamide to supplement CO2 angiography in patients with renal insufficiency,” Journal of Vascular and Interventional Radiology, vol. 11, no. 1, pp. 35–43, 2000. View at Google Scholar
  113. C. M. Erley, B. D. Bader, E. D. Berger et al., “Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotaemic patients,” Nephrology Dialysis Transplantation, vol. 19, no. 10, pp. 2526–2531, 2004. View at Publisher · View at Google Scholar · View at PubMed
  114. C. Briguori, A. Colombo, F. Airoldi et al., “Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures,” Catheterization and Cardiovascular Interventions, vol. 67, no. 2, pp. 175–180, 2006. View at Publisher · View at Google Scholar · View at PubMed
  115. P. S. Reed, S. R. Dixon, J. A. Boura, W. W. O'Neill, and J. K. Kahn, “Comparison of the usefulness of gadodiamide and iodine mixture versus iodinated contrast alone for prevention of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography,” American Journal of Cardiology, vol. 100, no. 7, pp. 1090–1093, 2007. View at Publisher · View at Google Scholar · View at PubMed
  116. T. F. Boyden and H. S. Gurm, “Does gadolinium-based angiography protect against contrast-induced nephropathy? A systematic review of the literature,” Catheterization and Cardiovascular Interventions, vol. 71, no. 5, pp. 687–693, 2008. View at Publisher · View at Google Scholar · View at PubMed
  117. A. J. Gauden, P. M. Phal, and K. J. Drummond, “MRI safety; nephrogenic systemic fibrosis and other risks,” Journal of Clinical Neuroscience, vol. 17, no. 9, pp. 1097–1104, 2010. View at Google Scholar
  118. M. R. Prince, H. L. Zhang, G. H. Roditi et al., “Risk factors for NSF: a literature review,” Journal of Magnetic Resonance Imaging, vol. 30, no. 6, pp. 1298–1308, 2009. View at Publisher · View at Google Scholar · View at PubMed